The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial
Status:
Recruiting
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
This is a randomized phase III trial that will randomize elderly patients(70 years of age and
older) who are not considered eligible for standard doublet or triplet regimens. In a 2:1
fashion, patients will be randomized to the customization arm or the standard arm,
respectively. This trial will be offered to patients who are previously untreated for stage
IV NSCLC.
The primary objective is to evaluate if chemotherapy selection based on histology and tumoral
molecular determinants ERCC1, RRM1 and TS (arm A, the experimental arm) results in superior
outcome in elderly patients with untreated, advanced NSCLC compared to standard of care
treatments (arm B, the standard arm).